Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Current Deferred Revenue (2023 - 2025)

Profound Medical has reported Current Deferred Revenue over the past 3 years, most recently at $445000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $445000.0 for Q4 2025, up 6.21% from a year ago — trailing twelve months through Dec 2025 was $445000.0 (up 6.21% YoY), and the annual figure for FY2025 was $445000.0, up 6.21%.
  • Current Deferred Revenue for Q4 2025 was $445000.0 at Profound Medical, up from $434000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PROF hit a ceiling of $721000.0 in Q4 2023 and a floor of $419000.0 in Q4 2024.
  • Median Current Deferred Revenue over the past 3 years was $540500.0 (2025), compared with a mean of $558166.7.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 41.89% in 2024 and later increased 6.21% in 2025.
  • Profound Medical's Current Deferred Revenue stood at $721000.0 in 2023, then tumbled by 41.89% to $419000.0 in 2024, then rose by 6.21% to $445000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $445000.0 (Q4 2025), $434000.0 (Q3 2025), and $694000.0 (Q2 2025) per Business Quant data.